Trial Profile

A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Loncastuximab tesirine (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Therapeutic Use
Sponsors Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Corporation

Most Recent Events

08 Jul 2025 Status changed from recruiting to active, no longer recruiting.
02 Nov 2023 According to Mitsubishi Tanabe Pharma Corporation media release, company announced initiation of the Phase 2 part of this study with MT-2111, ZYNLONTA (loncastuximab tesirinelpyl) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in Japan.
12 Jan 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com